According to the National Health and Health Commission, as of April 7, 2022, 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps have reported 3,289.463 million doses of the new coronavirus vaccine. At present, the safety of the new crown vaccine is high enough, but for some special groups, further research is still needed. On March 23, The Lancet AIDS magazine published online a prospective cohort study from Sao Paulo, Brazil, evaluating the immunogenicity and Safety is also the largest study of its kind to date. The study enrolled 511 participants between February 9, 2021 and March 4, 2021, of whom 215 (42%) were HIV-positive and 296 (58%) were HIV-uninfected as controls Group. The results showed that in HIV-infected patients, Clarifol had strong immunogenicity, and the incidence of adverse events was not significantly different from that in the control group. During the study period, the AIDS clinic at the University of Sao Paulo treated HIV-infected individuals aged 18 years and older who were vaccinated with Clarifol (70% of infected individuals had a CD4 cell count ≥ 5 .
[related_posts_by_tax taxonomies=”post_tag”]
The post China Kexing’s new crown vaccine for AIDS patients: good immunogenicity and safety appeared first on Gamingsym.